ATE481093T1 - Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit - Google Patents
Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheitInfo
- Publication number
- ATE481093T1 ATE481093T1 AT06025392T AT06025392T ATE481093T1 AT E481093 T1 ATE481093 T1 AT E481093T1 AT 06025392 T AT06025392 T AT 06025392T AT 06025392 T AT06025392 T AT 06025392T AT E481093 T1 ATE481093 T1 AT E481093T1
- Authority
- AT
- Austria
- Prior art keywords
- disease
- prevention
- treatment
- alzeheimer
- dexrazoxane
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title abstract 3
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 title 1
- 229960000605 dexrazoxane Drugs 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 230000004707 G1/S transition Effects 0.000 abstract 1
- 230000022131 cell cycle Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 1
- 229960002930 sirolimus Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0117645.2A GB0117645D0 (en) | 2001-07-19 | 2001-07-19 | Therapeutic stratergies for prevention and treatment of alzheimers disease |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE481093T1 true ATE481093T1 (de) | 2010-10-15 |
Family
ID=9918826
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06025393T ATE524169T1 (de) | 2001-07-19 | 2002-07-19 | Therapeutische strategien für die prävention und behandlung der alzeheimer-krankheit |
AT06025394T ATE535236T1 (de) | 2001-07-19 | 2002-07-19 | Therapeutische strategien für die prävention und behandlung der alzheimer-krankheit |
AT06025392T ATE481093T1 (de) | 2001-07-19 | 2002-07-19 | Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06025393T ATE524169T1 (de) | 2001-07-19 | 2002-07-19 | Therapeutische strategien für die prävention und behandlung der alzeheimer-krankheit |
AT06025394T ATE535236T1 (de) | 2001-07-19 | 2002-07-19 | Therapeutische strategien für die prävention und behandlung der alzheimer-krankheit |
Country Status (7)
Country | Link |
---|---|
US (2) | US8343926B2 (de) |
EP (9) | EP2292240A1 (de) |
AT (3) | ATE524169T1 (de) |
DE (1) | DE60237725D1 (de) |
ES (3) | ES2352964T3 (de) |
GB (1) | GB0117645D0 (de) |
WO (1) | WO2003007925A1 (de) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0117645D0 (en) | 2001-07-19 | 2001-09-12 | Isis Innovation | Therapeutic stratergies for prevention and treatment of alzheimers disease |
US7097996B2 (en) * | 2002-09-06 | 2006-08-29 | New York University | Methods of screening test compounds using GADD34L, an eIF2α-specific phosphatase subunit |
EP1558268A4 (de) * | 2002-09-17 | 2008-09-17 | Univ New York | Verfahren zur behandlung von altersassoziierten gedächtnisstörungen (aami), leichter kognitiver beeinträchtigung (mci) und demenzen mit zellzyklushemmern |
SI3424932T1 (sl) | 2005-02-16 | 2021-08-31 | Anacor Pharmaceuticals, Inc. | Boronoftalidi za terapevtsko uporabo |
EP1976536A4 (de) | 2005-12-30 | 2011-03-02 | Anacor Pharmaceuticals Inc | Borhaltige kleine moleküle |
PL1988779T3 (pl) * | 2006-02-16 | 2015-10-30 | Anacor Pharmaceuticals Inc | Małe cząsteczki zawierające bor jako środki przeciwzapalne |
EP2035003A1 (de) * | 2006-06-08 | 2009-03-18 | The Govt Of The USA, As Represented By The Secretary, Department Of Health And Human Services | Verfahren zur reduzierung der amyloid-beta-peptid-spiegel mit einem bisdioxopiperazin |
US8633179B2 (en) * | 2007-03-13 | 2014-01-21 | The Trustees Of Columbia University In The City Of New York | Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids |
JO3396B1 (ar) | 2007-06-20 | 2019-10-20 | Anacor Pharmaceuticals Inc | جزيئات صغيرة تحتوي على البورون |
EP3246034A1 (de) | 2008-03-06 | 2017-11-22 | Anacor Pharmaceuticals, Inc. | Boronhaltige kleinmoleküle als entzündungshemmende wirkstoffe |
WO2009140309A2 (en) * | 2008-05-12 | 2009-11-19 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
WO2010027975A1 (en) * | 2008-09-04 | 2010-03-11 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
WO2010028005A1 (en) | 2008-09-04 | 2010-03-11 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
WO2010045503A1 (en) * | 2008-10-15 | 2010-04-22 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as anti-protozoal agents |
CA2744231A1 (en) * | 2008-12-17 | 2010-07-15 | Anacor Pharmaceuticals, Inc. | Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol |
US8343944B2 (en) * | 2009-07-28 | 2013-01-01 | Anacor Pharmaceuticals, Inc. | Trisubstituted boron-containing molecules |
US9440994B2 (en) | 2009-08-14 | 2016-09-13 | Anacor Pharmaceuticals, Inc. | Boron containing small molecules as antiprotozoal agents |
MX2012002031A (es) * | 2009-08-19 | 2012-07-04 | Anacor Pharmaceuticals Inc | Moleculas pequeñas que contienen boro como agentes antiprotozoarios. |
WO2011037731A1 (en) * | 2009-09-25 | 2011-03-31 | Anacor Pharmaceuticals, Inc. | Boron containing small molecules |
US9346834B2 (en) | 2009-10-20 | 2016-05-24 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antiprotozoal agents |
US8461134B2 (en) * | 2009-11-11 | 2013-06-11 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
US8716478B2 (en) | 2010-01-27 | 2014-05-06 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
AP2012006482A0 (en) | 2010-03-19 | 2012-10-31 | Anacor Pharmacueticals Inc | Boron-containing small molecules as anti-protozoalagent |
CA2810021C (en) | 2010-09-07 | 2018-05-29 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
GB201112246D0 (en) * | 2011-07-15 | 2011-08-31 | Univ Birmingham | Diagnosis of alzheimer's disease |
EP2776018B1 (de) * | 2011-11-13 | 2021-08-25 | Cognitive Research Enterprises, Inc. | Pkc-aktivatoren und kombinationen davon |
WO2014018563A2 (en) * | 2012-07-23 | 2014-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for the treatment of cancer |
EP2906214A1 (de) | 2012-10-12 | 2015-08-19 | The Board of Regents of The University of Texas System | Verwendung von mtor-hemmern zur behandlung von vaskulären kognitiven störungen |
WO2014063105A1 (en) * | 2012-10-19 | 2014-04-24 | Celus Pharmaceuticals, Inc. | Vitamin d analogues for the treatment of a neurological disorder |
US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
CN104398523B (zh) * | 2014-11-03 | 2017-01-25 | 南昌大学 | (22反式)‑3β‑羟基‑胆甾‑5,22‑二烯‑24‑酮在神经保护药物中的应用 |
US11447506B2 (en) | 2016-05-09 | 2022-09-20 | Anacor Pharmaceuticals, Inc. | Crystal forms of crisaborole in free form and preparation method and use thereof |
WO2019032685A1 (en) * | 2017-08-08 | 2019-02-14 | Robert John Petcavich | FORMULATIONS FOR THE CONTRIBUTION OF TREHALOSE STIMULATING AUTOPHAGIA |
FR3091999A1 (fr) * | 2019-01-25 | 2020-07-31 | Mexbrain | Dispositif d’extraction conjointe d’un cation métallique et d’une molécule cible |
CN109678857B (zh) * | 2019-02-12 | 2020-08-14 | 宁波大学 | 一种鎓溴化物以及在神经退行性疾病药物的应用 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5242932A (en) | 1991-12-17 | 1993-09-07 | The Rockefeller University | Treatment of amyloidosis associated with alzheimer disease |
GB9211779D0 (en) * | 1992-06-03 | 1992-07-15 | Ciba Geigy Ag | Amine salts |
JPH09500087A (ja) | 1992-06-24 | 1997-01-07 | コーテックス ファーマシューティカルズ インコーポレイテッド | カルパイン活性の増大に関連した健康障害の抑制及び処置におけるカルパイン阻害剤の使用法 |
US5461146A (en) * | 1992-07-24 | 1995-10-24 | Cephalon, Inc. | Selected protein kinase inhibitors for the treatment of neurological disorders |
AU703667B2 (en) | 1994-09-20 | 1999-04-01 | Regents Of The University Of California, The | Drugs to improve synaptic transmission |
GB9521322D0 (en) * | 1995-10-17 | 1995-12-20 | Sandoz Ltd | Organic compounds |
TW427904B (en) * | 1995-12-07 | 2001-04-01 | American Home Prod | Neuroprotective agents |
US5846984A (en) * | 1996-01-19 | 1998-12-08 | The Trustees Of Columbia University In The City Of New York | Use of ciclopirox or a pharmaceutically acceptable salt thereof for inhibiting neuronal cell damage or neuronal cell death |
JPH09221421A (ja) * | 1996-02-13 | 1997-08-26 | Kyowa Hakko Kogyo Co Ltd | 抗アポトーシス剤 |
GB2314268A (en) * | 1996-06-18 | 1997-12-24 | Ciba Geigy Ag | Pulmonary administration of desferrioxamine-B salts |
GB9613182D0 (en) * | 1996-06-24 | 1996-08-28 | Nycomed Imaging As | Method |
FR2750991A1 (fr) * | 1996-07-12 | 1998-01-16 | Pf Medicament | Nouveaux benzodioxannes et 1-(2h)-benzopyrannes, leur preparation et leur utilisation comme medicament |
EP1006798A4 (de) * | 1996-09-05 | 2003-03-05 | Massachusetts Inst Technology | Zusammensetzungen und verfahren zur behandlung neurologischer störungen und neurodegenerativer erkrankungen |
US5922761A (en) * | 1996-09-06 | 1999-07-13 | Medinox, Inc. | Methods for in vivo reduction of iron levels and compositions useful therefor |
PE27799A1 (es) * | 1996-12-10 | 1999-03-18 | Novartis Ag | Formulaciones y formas polimorficas de desferrioxamina y su preparacion |
US6037488A (en) * | 1997-04-19 | 2000-03-14 | Allergan Sales, Inc. | Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity |
US5919970A (en) * | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
DE69841549D1 (de) * | 1997-05-14 | 2010-04-22 | Sloan Kettering Inst Cancer | Verfahren und zubereitungen zur zerstörung bestimmter proteine |
US6264994B1 (en) * | 1997-05-15 | 2001-07-24 | University Of Washington | Compositions for treating alzheimer's disease and other amyloidoses |
EP1051165A2 (de) * | 1998-01-26 | 2000-11-15 | Mitokor | Schutzmittel für mitochondrien zur behandlung von mitochondrialererkrankungen |
WO1999048489A2 (en) * | 1998-03-25 | 1999-09-30 | South Alabama Medical Science Foundation | Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders |
EP1239038A1 (de) * | 2001-03-07 | 2002-09-11 | Galapagos Genomics B.V. | Hochdurchsetz-Verfahren zur Identification von Modulatoren der E2F-Aktivität |
FR2780967B1 (fr) * | 1998-07-13 | 2000-09-29 | Pf Medicament | Procede de preparation de derives du 2,3-dihydrobenzofurane -2,2-disubstitues |
US20030044776A1 (en) | 1998-09-25 | 2003-03-06 | James A. Dykens | Compositions and methods for identifying agents that alter mitochondrial permeability transition pores |
EP1006108A1 (de) * | 1998-12-01 | 2000-06-07 | Cerebrus Pharmaceuticals Limited | 3-Hydroxy-2(1H)-pyridinon- oder 3-hydroxy-4(1H)-pyridinon- Derivate verwendbar als reaktive Sauerstoffspezies-Fänger (ROS) |
JP2000290184A (ja) * | 1999-04-01 | 2000-10-17 | Kyowa Hakko Kogyo Co Ltd | 経鼻投与製剤 |
FR2795727B1 (fr) * | 1999-06-29 | 2001-09-21 | Pf Medicament | Nouveaux derives benzodioxanne imidazolines fluores, leur preparation et leurs applications en therapeutique |
DE69903278D1 (de) * | 1999-07-09 | 2002-11-07 | Inst Pasteur De Lille Lille | Verfahren zur Diagnose oder zur Prognose von Alzheimer Krankheit: therapeutische Zusammensetzung zur Verhinderung oder zur Behandlung von Alzheimer Krankheit |
DK1206448T3 (da) * | 1999-08-04 | 2004-08-09 | Leo Pharma As | Nye vitamin D analoger |
WO2001012236A2 (en) | 1999-08-18 | 2001-02-22 | The General Hospital Corporation | Methods, compositions and kits for promoting recovery from damage to the central nervous system |
CN1168726C (zh) * | 2000-01-10 | 2004-09-29 | 里奥制药有限公司 | 新的维生素d类似物 |
AU2001228330A1 (en) * | 2000-01-31 | 2001-08-14 | Leo Pharma A/S | Vitamin d-derivatives and their use in treating osteoporosis and related bone disorders |
GB0106051D0 (en) | 2001-03-12 | 2001-05-02 | Isis Innovation | Diagnostic screens for alzheimer's disease |
GB0117645D0 (en) | 2001-07-19 | 2001-09-12 | Isis Innovation | Therapeutic stratergies for prevention and treatment of alzheimers disease |
WO2003083067A2 (en) * | 2002-03-28 | 2003-10-09 | Brigham And Women's Hospital, Inc. | Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease |
US20050234063A1 (en) | 2002-06-28 | 2005-10-20 | Kazuhiro Terai | Therapeutic agent for brain hemorrhage |
GB0311835D0 (en) | 2003-05-22 | 2003-06-25 | Isis Innovation | Susceptibility gene for alzheimer's disease |
-
2001
- 2001-07-19 GB GBGB0117645.2A patent/GB0117645D0/en not_active Ceased
-
2002
- 2002-07-19 EP EP10176675A patent/EP2292240A1/de not_active Withdrawn
- 2002-07-19 EP EP10176688A patent/EP2286875A1/de not_active Withdrawn
- 2002-07-19 WO PCT/GB2002/003327 patent/WO2003007925A1/en not_active Application Discontinuation
- 2002-07-19 ES ES06025392T patent/ES2352964T3/es not_active Expired - Lifetime
- 2002-07-19 EP EP06025392A patent/EP1769791B1/de not_active Expired - Lifetime
- 2002-07-19 EP EP10176681A patent/EP2286803A1/de not_active Withdrawn
- 2002-07-19 AT AT06025393T patent/ATE524169T1/de not_active IP Right Cessation
- 2002-07-19 ES ES06025393T patent/ES2373565T3/es not_active Expired - Lifetime
- 2002-07-19 EP EP10176686A patent/EP2289511A1/de not_active Withdrawn
- 2002-07-19 US US10/200,023 patent/US8343926B2/en not_active Expired - Fee Related
- 2002-07-19 EP EP10176680A patent/EP2292238A1/de not_active Withdrawn
- 2002-07-19 EP EP06025394A patent/EP1764092B1/de not_active Expired - Lifetime
- 2002-07-19 ES ES06025394T patent/ES2375293T3/es not_active Expired - Lifetime
- 2002-07-19 DE DE60237725T patent/DE60237725D1/de not_active Expired - Lifetime
- 2002-07-19 AT AT06025394T patent/ATE535236T1/de active
- 2002-07-19 AT AT06025392T patent/ATE481093T1/de not_active IP Right Cessation
- 2002-07-19 EP EP06025393A patent/EP1767197B1/de not_active Expired - Lifetime
- 2002-07-19 EP EP02749036A patent/EP1408938A1/de not_active Ceased
-
2012
- 2012-11-30 US US13/690,646 patent/US8921321B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP2292238A1 (de) | 2011-03-09 |
EP1767197B1 (de) | 2011-09-14 |
EP1769791B1 (de) | 2010-09-15 |
EP2286875A1 (de) | 2011-02-23 |
ES2375293T3 (es) | 2012-02-28 |
ES2373565T3 (es) | 2012-02-06 |
EP2286803A1 (de) | 2011-02-23 |
EP2292240A1 (de) | 2011-03-09 |
EP2289511A1 (de) | 2011-03-02 |
ATE524169T1 (de) | 2011-09-15 |
EP1767197A2 (de) | 2007-03-28 |
US20030032673A1 (en) | 2003-02-13 |
EP1767197A3 (de) | 2007-05-30 |
US8343926B2 (en) | 2013-01-01 |
ATE535236T1 (de) | 2011-12-15 |
ES2352964T3 (es) | 2011-02-24 |
DE60237725D1 (de) | 2010-10-28 |
EP1769791A2 (de) | 2007-04-04 |
GB0117645D0 (en) | 2001-09-12 |
EP1764092A2 (de) | 2007-03-21 |
EP1408938A1 (de) | 2004-04-21 |
EP1769791A3 (de) | 2007-07-11 |
EP1764092B1 (de) | 2011-11-30 |
WO2003007925A1 (en) | 2003-01-30 |
US8921321B2 (en) | 2014-12-30 |
US20130102553A1 (en) | 2013-04-25 |
EP1764092A3 (de) | 2007-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE481093T1 (de) | Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit | |
DE60112055D1 (de) | Inhibitoren von gamma-secretase | |
DE60216275D1 (de) | Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer-krankheit | |
NO20045281L (no) | Tiazolidinoner og anvendelse derav som polo-lignende kinaseinhibitorer | |
IS7325A (is) | alfa-(N-súlfonamíðó)acetamíð afleiður sem beta-amýlóíð tálmar | |
ATE454378T1 (de) | Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen | |
ATE354563T1 (de) | Sulfonderivate zur hemmung von gamma-secretase | |
NO20054905L (no) | 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika | |
ATE401314T1 (de) | Benzodiazepin-derivate als gamma-secretase inhibitoren | |
DE60003863D1 (de) | Dioxocyclopentylhydroxamsäure | |
NO20053263D0 (no) | Hydroksyetylaminderivater for behandling av Alzheimers sykdom. | |
YU17003A (sh) | Spiroheterociklični nitrili upotrebljivi kao reverzibilni inhibitori cisteinskih proteaza | |
CY1110745T1 (el) | Παραγωγα πυρρολιδονης ως αναστολεις μαοβ | |
ATE357438T1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
PE20030061A1 (es) | 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4 | |
ATE349448T1 (de) | Pyrazol-3,4-d-pyrimidinderivate und ihre verwendung bei der behandlung von h.pylori- infektionen | |
DE60115466D1 (de) | Wirkstoffvorläufer von imidazopyridin-derivaten | |
DE60108626D1 (de) | Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer | |
EA200301101A1 (ru) | Производные пиперазина и их применение в качестве ингибиторов pde4 | |
NZ511997A (en) | Isonipecotamides for the treatment of integrin-mediated disorders | |
DE602004010186D1 (de) | Diazaspiropiperidinderivate als inhibitoren von glycintransporter 1 und glycintransporter 2 | |
MY136138A (en) | Hexacyclic compounds | |
ATE358487T1 (de) | Kombination enthaltend cyamemazine und ein atypisches neuroleptikum | |
ATE439848T1 (de) | Verwendung von naringenin, naringin und salzen daraus als schleimlíser bei der behandlung von husten sowie zusammensetzungen daraus | |
DK1358182T3 (da) | Diazocin-derivater og anvendelsen deraf som tryptase-inhibitorer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |